Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY3200327 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Placebo (SC) | PLACEBO_COMPARATOR | Single subcutaneous (SC) dose of placebo |
| LY3200327 (SC) | EXPERIMENTAL | Single escalating subcutaneous (SC) dose of LY3200327 |
| LY3200327 (IV) | EXPERIMENTAL | Single intravenous (IV) dose of LY3200327 |
| Placebo (IV) | PLACEBO_COMPARATOR | Single intravenous (IV) dose of placebo |
| Name | Type | Description |
|---|---|---|
| Placebo (SC) | DRUG | Administered SC |
| LY3200327 (SC) | DRUG | Administered SC |
| LY3200327 (IV) | DRUG | Administered IV |
| Placebo (IV) | DRUG | Administered IV |
Inclusion Criteria: * At the time of initial screening, in general good health * First-generation healthy Japanese (age 20 to 65 years) will be included Exclusion Criteria: * Pregnancy or breastfeeding during the study * Chronic infection * Treatment with prohibited medications
LY3200327 is an investigational small molecule being developed by Eli Lilly and Company. It is currently in Phase 1 clinical development for use in healthy participants. The drug has been studied in a completed clinical trial, but it is not yet approved and remains under investigation.
LY3200327 is being studied for use in healthy participants. The completed Phase 1 trial evaluated the drug in healthy volunteers to assess its safety and tolerability. It is not approved for any specific medical condition and is still in early clinical development.
LY3200327 is being developed by Eli Lilly and Company, a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol LLY. The company is conducting clinical research on this investigational small molecule drug.
LY3200327 is in Phase 1 clinical development. A Phase 1 trial has been completed, and the drug remains investigational. It has not been approved by regulatory authorities and is still undergoing clinical evaluation.
LY3200327 has one completed clinical trial, identified as NCT02595736, titled "A Study of LY3200327 in Healthy Participants." This Phase 1 study enrolled 52 participants in the United States and was a randomized, double-blind, placebo-controlled trial.
LY3200327 is the primary name for this investigational drug. No alternative names have been established in the available clinical trial information. It is being studied under this identifier in the completed Phase 1 trial.